BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Aegera Therapeutics

Aegera Therapeutics logo

Founded
1997
Clinical Trials
9

Technologies

Antisense Oligonucleotides

Aegera Therapeutics, part of Pharmascience Inc., is focused on developing targeted therapeutics to address major unmet medical needs.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain.

Aegera is also dedicated to identifying novel development candidates based upon its core technologiesand internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials.


Posts Mentioning This Company

Antisense Oligonucleotides Make Sense

  
Antisense oligonucleotides (ASOs) are short (about 12 to 25 nucleotides long), synthetic single strands of DNA or RNA that are complementary to a chosen sequence. They can alter RNA and reduce, restore, or modify protein expression. ASOs interact with proteins on the surface of cells and enter the cytoplasm. Then …
SHARE